UCB unveils Neupro drug in US market
Neupro received the US Food and Drug Administration approval on 3 April 2012. UCB CEO Roch Doliveux said the availability of Neupro is an important step forward for
The US Food and Drug Administration (FDA) has granted priority review to Roche’s supplemental biologics licence application (sBLA) for Gazyva/Gazyvaro (obinutuzumab) to treat adults with primary membranous nephropathy (pMN).